Immunodeficiency

Job Research Foundation Awards Fourth Grant to Germany-Based Researcher to Investigate Causes of and Treatments for Job Syndrome

Retrieved on: 
火曜日, 6月 18, 2019
Medical specialties, Hyperimmunoglobulin E syndrome, Pediatrics, Immunodeficiency, Health, Medicine

NEW YORK, June 18, 2019 /PRNewswire-PRWeb/ --The Job Research Foundation is pleased to announce the fourth grant recipient of the first round of funding to support investigation into the causes of and treatments for Job Syndrome.

Key Points: 
  • NEW YORK, June 18, 2019 /PRNewswire-PRWeb/ --The Job Research Foundation is pleased to announce the fourth grant recipient of the first round of funding to support investigation into the causes of and treatments for Job Syndrome.
  • The $200,000 grant has been awarded to Dr. Ellen D. Renner, Translational Immunology in Environmental Medicine - TU Munich and Helmholtz Zentrum Mnchen, Germany.
  • The grant will be awarded over a 24-month period.
  • Job Syndrome, also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), was discovered in 1966 and is a multisystem immunodeficiency disorder found in males and females worldwide.

X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease

Retrieved on: 
水曜日, 6月 12, 2019
Health, Biotechnology, Genetics, Pharmaceutical, Research, Science, Immunodeficiency, Primary immunodeficiency, Cancer

Simultaneously, this partnership provides X4 with a clear path to gather critical data to identify the underlying genetic causes of PIs and deepen our understanding of these patients potential to respond to novel investigational therapies.

Key Points: 
  • Simultaneously, this partnership provides X4 with a clear path to gather critical data to identify the underlying genetic causes of PIs and deepen our understanding of these patients potential to respond to novel investigational therapies.
  • If the initial testing does not show mutations associated with WHIM or SCN, physicians will be able to access a broader PI panel through the program for expanded patient testing.
  • X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers.
  • Global study of primary immunodeficiency diseases (PI) diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation.

X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia

Retrieved on: 
水曜日, 5月 15, 2019
Health, Biotechnology, Cardiology, Clinical trials, Genetics, Oncology, Pharmaceutical, Research, Science, RTT, Medical specialties, Lymphoma, Medicine, Clinical medicine, Non-Hodgkin lymphoma, Infectious causes of cancer, Lymphoproliferative disorders, Cancer, Immunodeficiency, Primary immunodeficiency, Waldenström's macroglobulinemia

LLSs selection of mavorixafor for TAP collaboration and investment reinforces its potential as a novel therapy for Waldenstrms macroglobulinemia.

Key Points: 
  • LLSs selection of mavorixafor for TAP collaboration and investment reinforces its potential as a novel therapy for Waldenstrms macroglobulinemia.
  • Waldenstrms macroglobulinemia (WM) is a rare form of non-Hodgkin lymphoma and B-cell lymphoproliferative disorder.
  • X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers.
  • X4 undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Octapharma Study Presented at CIS Demonstrates cutaquig® Efficacy and Safety

Retrieved on: 
月曜日, 5月 6, 2019
Health, Pharmaceutical, Research, Science, General Health, Medicine, Clinical medicine, Branches of biology, Glycoproteins, Immunoglobulin therapy, RTT, Transfusion medicine, Primary immunodeficiency, Immunodeficiency, Tolerability, Octapharma

Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies, said Octapharma USA President Flemming Nielsen.

Key Points: 
  • Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies, said Octapharma USA President Flemming Nielsen.
  • The evaluation of adverse events and infusion site reactions during the study showed that subcutaneous administration of cutaquig was well tolerated and safe in the assessed patient population.
  • The clinical trials primary endpoint of preventing serious bacterial infections (SBIs) was met as none of the patients experienced an SBI during the study.
  • Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig]) in the Treatment of Patients With Primary Immunodeficiencies.

Primary Immune Deficiency (PID) Therapeutics Pipeline Review, H1 2019 Edition - ResearchAndMarkets.com

Retrieved on: 
月曜日, 4月 8, 2019
Health, Pharmaceutical, Immunodeficiency, Primary immunodeficiency, PID

The "Primary Immune Deficiency (PID) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Primary Immune Deficiency (PID) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Primary Immune Deficiency (PID) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Primary Immune Deficiency (PID) - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
月曜日, 4月 8, 2019
Retail, Other Retail, Health sciences, Immunodeficiency, Health, Primary immunodeficiency, Articles, Pipeline, Therapy

The "Primary Immune Deficiency (PID) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Primary Immune Deficiency (PID) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Primary Immune Deficiency (PID) development.
  • The report covers pipeline activity across the complete product development cycle i.e.
  • clinical, pre-clinical and discovery stages for Primary Immune Deficiency (PID)
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Primary Immune Deficiency (PID)
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting

Retrieved on: 
火曜日, 2月 5, 2019
Health, Biotechnology, Clinical trials, Infectious diseases, Pharmaceutical, Research, Science, Managed care, Fungi, Holomycota, Medical specialties, Antifungals, Yeasts, Echinocandins, Gut flora, Pathogenic microbes, Immunodeficiency, Pathogenic fungus, Mycosis, Aspergillus

Invasive fungal infections (IFIs) are a leading cause of morbidity and mortality among immunocompromised patients, particularly those undergoing blood and marrow transplantation.

Key Points: 
  • Invasive fungal infections (IFIs) are a leading cause of morbidity and mortality among immunocompromised patients, particularly those undergoing blood and marrow transplantation.
  • Rezafungin is a novel antifungal echinocandin being developed as a once-weekly therapy for the prevention of IFIs caused by the most common fungal pathogens: Candida, Aspergillus and Pneumocystis.
  • The TCT Meeting convenes more than 3,700 attendees to present and discuss recent progress in basic science, translational research and clinical studies in all areas of blood and marrow transplantation and cellular therapy.
  • Copies of the posters will be available on the Cidara website following the meeting: www.cidara.com .

U.S. Intravenous Immunoglobulin (IVIG) Market Analysis & Outlook (2018-2025): Stringent Regulations Pertaining to Production & Approval is Hampering Growth

Retrieved on: 
木曜日, 11月 8, 2018
Medicine, Immunology, Clinical medicine, Immunodeficiency, Primary immunodeficiency, Immunoglobulin therapy, Gamma globulin, Hypogammaglobulinemia, HIV/AIDS, Selective immunoglobulin A deficiency

The U.S. intravenous immunoglobulin (IVIG) market size is expected to reach USD 5.04 billion by 2025.

Key Points: 
  • The U.S. intravenous immunoglobulin (IVIG) market size is expected to reach USD 5.04 billion by 2025.
  • The market is estimated to witness a noteworthy CAGR of 6.1% over the forecast period.
  • Rising prevalence of primary and acquired immunodeficiency diseases such as congenital AIDS and hypogammaglobulinemia is a major growth driver of this market.
  • Rising cases of primary immune deficiency diseases are expected to drive the demand for fast, accurate, and safe treatment options, thereby boosting the market growth.

Multiple Studies Presented at IDWeek 2018 Highlight Use of Karius Test as a Liquid Biopsy for Infectious Diseases

Retrieved on: 
月曜日, 10月 8, 2018
Medicine, RTT, Infectious diseases, Infective endocarditis, Valvular heart disease, Health, Infection, Febrile neutropenia, Immunodeficiency, Clinical medicine

Clinical applications regarding use of the Karius Test as a liquid biopsy for infectious diseases were the focus of the presentations.

Key Points: 
  • Clinical applications regarding use of the Karius Test as a liquid biopsy for infectious diseases were the focus of the presentations.
  • Oral abstracts, poster presentations and a Learning Lounge allowed collaborators to present their experiences with the Karius Test.
  • "The clinical studies presented by our colleagues cover some of the most challenging infectious diseases scenarios such as infective endocarditis, bloodstream infections in immunocompromised patients, invasive fungal infections, and febrile neutropenia."
  • The Karius Test combines advanced genomic diagnostics for pathogen detection with expansive microbial data analytics and a rapid computational platform.

Primary Immunodeficiency Diseases Epiomic Epidemiology Markets, 2018-2028 - Focus on 23 Key Countries

Retrieved on: 
水曜日, 9月 19, 2018
Medicine, Immunology, Immunodeficiency, Primary immunodeficiency, Health, Immune system, Disease, PID, Immune disorder, Autoimmunity

The "Epiomic Epidemiology Series: Primary Immunodeficiency Diseases Forecast In 23 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Epiomic Epidemiology Series: Primary Immunodeficiency Diseases Forecast In 23 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • Primary immunodeficiency diseases (PID) are a group of inherited genetic disorders of the genes governing the immune system.
  • PIDs are a group of more than 200 rare, chronic disorders in which part of the body's immune system is missing or functions improperly.
  • Some types of PID affect a single part of the immune system while others may affect one or more components of the system.